Our mission is to improve patient care by providing clinicians with life-saving cardiac diagnostic products. With a focus on accuracy and timeliness, we empower physicians to deliver superior care through complete control of the diagnostic process.
We are committed to our core values, including customer satisfaction, accountability, integrity, respect, trust, ethics, and excellence, ensuring optimized diagnosis. Join us in transforming cardiac healthcare for the better.
Provide life-saving ECG diagnostics for everyone.
Cardiac Insight strives to improve the quality of patient care with innovative cardiac diagnostic products that help clinicians save lives.
Empowering physicians to provide superior care by fully controlling the optimized diagnostic process.
Our mission is to improve patient care by providing clinicians with life-saving cardiac diagnostic products. With a focus on accuracy and timeliness, we empower physicians to deliver superior care through complete control of the diagnostic process.
We are committed to our core values, including customer satisfaction, accountability, integrity, respect, trust, ethics, and excellence, ensuring the optimized diagnosis. Join us in transforming cardiac healthcare for the better.
Provide life-saving ECG diagnostics for everyone.
Cardiac Insight strives to improve the quality of patient care with innovative cardiac diagnostic products that help clinicians save lives.
Empowering physicians to provide superior care by fully controlling the optimized diagnostic process.
Min Kim serves as the CEO of both Cardiac Insight and Dreamtech, a parent company of Cardiac Insight.
Since joining Dreamtech in 2014, Mr. Kim has orchestrated multiple international strategic alliances and M&A deals, bolstering the company’s competitiveness in medical device development and manufacturing. In early 2019, he led the company to a successful IPO on KOSPI, achieving a remarkable market capitalization of $600 million.
Prior to his tenure at Dreamtech, Mr. Kim held pivotal roles at renowned investment banking firms, including Samsung Securities and Lehman Brothers, where he significantly contributed to M&A and fundraising transactions surpassing $5 billion.
He holds an MBA from the Wharton School of the University of Pennsylvania and a B.S. in Finance from the University of Southern California.
With a Ph.D. in Geophysics and Seismology from Caltech, Dr. Hadley co-founded Sierra Geophysics during his graduate years, which later transitioned into a successful software company for the oil and gas exploration industry.
He went on to lead several companies in the diagnostic cardiology field, including Quinton Cardiology, where he rebuilt the engineering team and developed various products.
As the former Chief Technology Officer of Cardiac Insight, Dr. Hadley collaborated with Dr. Victor Froelicher, now the Chief Medical Officer at Cardiac Insight and a former professor of medicine and consultant in Sports Cardiology at Stanford Health Care, resulted in important research on ECG analysis and the development of the “Stanford Criteria.” Their efforts culminated in creating Cardea 20/20, utilizing the “International Consensus Criteria” to make ECG screening economical and valuable.
Dr. Vic Froelicher, an Emeritus Professor of Medicine and longtime Sports Cardiology Consultant at Stanford Healthcare, has had an illustrious career in cardiology. He began his journey at the USAF School of Aerospace Medicine, where he screened pilots, astronauts, and military athletes. A leading expert in clinical exercise physiology and ECG interpretation, Dr. Froelicher co-authored the influential textbook “Exercise and the Heart.”
Dr. Froelicher’s contributions to the field are significant. He played a pivotal role in developing the first international consensus document to specify ECG criteria to reduce false positives in screening athletes for sudden cardiac death and contributed to the Olympic Committee’s 2017 Cardiology Manual. As a major consultant to Stanford Sports Medicine, his knowledge and insight have shaped sports cardiology practices for over three decades.
Having previously served as an Executive Advisor at Cardiac Insight, Dr. Froelicher is now the Chief Medical Officer, where his extensive experience continues to advance technology in cardiac care.
Before joining Cardiac Insight, Roy Kim was a Senior Vice President & Area Banking Manager at Hanmi Bank in Los Angeles, California. He was responsible for managing a commercial portfolio with over $500 million in assets and liabilities of over $1.2 billion.
He was also accountable for overall team leadership and financial management, including overseeing credit portfolios and client deposit relationships for the past 26 years.
He holds a B.S. in Finance from the University of Southern California and a Certificate of Global CEO program from Yeonsei University.
A 35+ year veteran in medical device development, Dan Tylutki, holds a Master of Science in Electrical Engineering from Santa Clara University, and a Bachelor of Science in Electrical Engineering from the University of Idaho.
He was responsible for product development management, project management, medical device quality systems, and regulatory affairs for various industry leaders, including Varian Medical Systems, Wavtrace, Mindplay, Northstar Neuroscience, and Light Sciences Oncology.
He brings his FDA class II/III medical device development to Cardiac Insight, with a mission to enhance the quality of life for patients and their families.
Ram Chintala brings over two decades of expertise in healthcare technology, specializing in architecting advanced medical devices. As Co-Founder of Moaizone, he is developing intelligent edge devices for remote elder care using AI/ML frameworks and ARM-based systems. At Siemens Healthcare, he led the development of cutting-edge ultrasound devices, implementing software DFMEA and optimizing diagnostic reliability.
With expertise in embedded systems, FDA-compliant software, and cloud solutions, Ram holds a Master’s degree in Electrical and Computer Engineering from Ohio University and a Bachelor’s in Electronics Engineering from M S Ramaiah Institute of Technology, Bangalore.
Abby is a cardiovascular healthcare leader with more than 20 years of experience across clinical care, operations, and commercial leadership. She began her career as a Registered Cardiovascular Invasive Specialist (RCIS) and advanced into senior leadership roles, driving improvements in clinical performance, workforce engagement, and operational consistency.
Known for building high-performing teams, she reduced turnover in hospital cardiovascular units before transitioning into senior commercial leadership. As Senior Director of Sales, Abby delivered 30% year-over-year growth while scaling a stable, standardized sales organization.
She holds a master’s degree in educational technology from the University of Texas, is RCIS-certified, and has formal training in instructional design with experience across radiology specialties.
Dr. Jonathan Drezner is a Professor in the Department of Family Medicine and Director of the UW Medicine Center for Sports Cardiology at the University of Washington (Seattle – USA). He serves as Editor-in-Chief of the British Journal of Sports Medicine, and he is Team Physician for the Seattle Seahawks (NFL), Seattle Reign (NWSL), and the University of Washington. Dr. Drezner is past-President of the American Medical Society for Sports Medicine (AMSSM, 2012-13) and Director of the Division for Cardiac Injury in Sport for the National Center for Catastrophic Sports Injury Research. Dr. Drezner has dedicated his career to the prevention of sudden cardiac arrest and death (SCA/D) in young athletes and the development of effective models for prevention. His primary research has focused on the incidence and etiology of SCA/D, cardiovascular screening and ECG interpretation in athletes, and emergency response planning and the use of automated external defibrillators (AEDs) in the school and athletic settings. He is co-PI and founder of the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA) study designed to monitor health outcomes in competitive athletes diagnosed with pathologic cardiac disorders.
Dr. Drezner has chaired or co-chaired several fundamental consensus statements to advance the cardiovascular care of athletes including: the 2007 inter-association task force on emergency preparedness and the management of sudden cardiac arrest in high school and college athletic programs; the 2016 AMSSM position statement on cardiovascular screening in athletes; and the 2013 Seattle Criteria and 2017 International Criteria for ECG interpretation in athletes which emerged as the contemporary standard to distinguish physiologic ECG findings from abnormalities suggestive of a pathologic cardiac disorder. He also chaired the 2025 International Summit on ECG Interpretation in Athletes with anticipated updates to the International Criteria. Dr. Drezner has presented his research in sports cardiology both nationally and internationally and has over 230 peer-reviewed publications.
Dr. Jonathan Drezner is a Professor in the Department of Family Medicine and Director of the UW Medicine Center for Sports Cardiology at the University of Washington (Seattle – USA). He serves as Editor-in-Chief of the British Journal of Sports Medicine, and he is Team Physician for the Seattle Seahawks (NFL), Seattle Reign (NWSL), and the University of Washington. Dr. Drezner is past-President of the American Medical Society for Sports Medicine (AMSSM, 2012-13) and Director of the Division for Cardiac Injury in Sport for the National Center for Catastrophic Sports Injury Research. Dr. Drezner has dedicated his career to the prevention of sudden cardiac arrest and death (SCA/D) in young athletes and the development of effective models for prevention. His primary research has focused on the incidence and etiology of SCA/D, cardiovascular screening and ECG interpretation in athletes, and emergency response planning and the use of automated external defibrillators (AEDs) in the school and athletic settings. He is co-PI and founder of the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA) study designed to monitor health outcomes in competitive athletes diagnosed with pathologic cardiac disorders.
Dr. Drezner has chaired or co-chaired several fundamental consensus statements to advance the cardiovascular care of athletes including: the 2007 inter-association task force on emergency preparedness and the management of sudden cardiac arrest in high school and college athletic programs; the 2016 AMSSM position statement on cardiovascular screening in athletes; and the 2013 Seattle Criteria and 2017 International Criteria for ECG interpretation in athletes which emerged as the contemporary standard to distinguish physiologic ECG findings from abnormalities suggestive of a pathologic cardiac disorder. He also chaired the 2025 International Summit on ECG Interpretation in Athletes with anticipated updates to the International Criteria. Dr. Drezner has presented his research in sports cardiology both nationally and internationally and has over 230 peer-reviewed publications.
He is a nationally recognized expert in hypertrophic cardiomyopathy and cardiovascular care of athletes.
Board-certified in cardiovascular disease and fellowship-trained at the Mayo Clinic, Dr. Martinez serves as a league cardiologist to Major League Soccer (MLS), the National Football League (NFL) and National Hockey League (NHL) Combines, and the Jets and National Basketball Association (NBA) Players Associations. He specializes in the evaluation of structural and inherited heart disease in both symptomatic and asymptomatic athletes using advanced cardiac imaging.
The current President of the HCM society and a past Chair of the American College of Cardiology’s Sports and Exercise Section and recipient of the ACC Emerging Faculty Award, Dr. Martinez is a leading educator and speaker on sudden cardiac arrest and cardiovascular risk in athletes.
Dr. Marco Perez is Associate Professor of Cardiovascular Medicine at Stanford University and Director of the Stanford Inherited Cardiac Arrhythmia Clinic and Electrocardiography Department. A board-certified cardiac electrophysiologist, he specializes in inherited arrhythmia syndromes, sports electrophysiology, atrial fibrillation, and digital health-enabled cardiac monitoring.
Dr. Perez served as Co-Principal Investigator of the landmark Apple Heart Study and is Clinical Coordinating Center PI of the NIH-funded REACT-AF trial evaluating smartwatch-guided anticoagulation strategies. His research integrates genomics, artificial intelligence, and wearable ECG technologies to advance early detection and precision management of cardiac arrhythmias.
An Associate Editor of Circulation: Arrhythmia & Electrophysiology and contributor to national atrial fibrillation guidelines, Dr. Perez is internationally recognized for advancing the clinical integration of digital cardiovascular technologies and data-driven care.
Dr. Rasham Sandhu obtained his medical degree from Gorakhpur University/Baba Raghav Das Medical College and completed his Internal Medicine residency and Cardiovascular Fellowship at Westchester Medical Center in Valhalla, New York. He is board-certified in Interventional Cardiology, Cardiovascular Disease, and Nuclear Cardiology. He first came to California in 2011, joining a prominent cardiology group in Bakersfield focused on delivering the best care possible using the most current treatment plans.
His dedication to transform care for those with chronic health conditions, led him to start the California Cardiovascular Institute, his own private medical group in 2022. Dr. Sandhu is recognized as one of the leading cardiologists in the Central Valley having earned his reputation from his practice and writings (in books and research studies) and is a sought-after speaker at national conferences.
Dr. Sandhu is also the founder of two non-profit organizations, Thrive & Purpose Foundation and Heart of the City Foundation, and currently serves as a board member of Adventist Health Central Valley. Passionate about health and wellness, Dr. Sandhu is committed to improving the well-being of his community in Central Valley.
After earning a B.S. in Biochemistry from UCLA in 2000, James pursued a Pharm.D. degree from the prestigious University of the Pacific School of Pharmacy, graduating in 2003. The early years of James Pai’s career were marked by valuable experience at both Sav-on Pharmacy and Costco Pharmacy from 2003 to 2011.
In 2007, the entrepreneurial spirit and a commitment to exceptional patient service made James Pai establish independent pharmacies, demonstrating a remarkable blend of business acumen and pharmaceutical expertise.